Tafamidis Patent Expiration

Tafamidis is used for treating cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) It was first introduced by Foldrx Pharmaceuticals Llc A Wholly Owned Sub Of Pfizer Inc in its drug Vyndamax on May 3, 2019.


Tafamidis Patents

Given below is the list of patents protecting Tafamidis, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vyndamax US7214695 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding Dec 19, 2024 Foldrx Pharms
Vyndamax US7214696 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding Dec 19, 2024 Foldrx Pharms
Vyndamax US9770441 Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole Aug 31, 2035 Foldrx Pharms


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tafamidis's patents.

Given below is the list recent legal activities going on the following patents of Tafamidis.

Event Date Patent/Publication
Patent litigations
Second letter to regulating agency to determine regulatory review period 29 Apr, 2024 US7214695
Second letter to regulating agency to determine regulatory review period 29 Apr, 2024 US7214696
Letter from FDA or Dept of Agriculture re PTE application 08 Feb, 2024 US7214695
Letter from FDA or Dept of Agriculture re PTE application 08 Feb, 2024 US7214696
Interim Patent Term Extension Granted 13 Oct, 2023 US7214695
Interim Patent Term Extension Granted 13 Oct, 2023 US7214696
Initial letter Re: PTE Application to regulating agency 31 Mar, 2022 US7214695
Initial letter Re: PTE Application to regulating agency 31 Mar, 2022 US7214696
Payment of Maintenance Fee, 4th Year, Large Entity 28 Sep, 2020 US9770441
Post Issue Communication - Certificate of Correction 14 May, 2020 US7214696



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳